Novavax Succeeds In Phase III Flu Vaccine Trial Against Sanofi’s Fluzone
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.
You may also be interested in...
Pioneer of nanoparticle vaccine technology is latest to get financial backing from the foundation.
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
As the coronavirus continues its global spread, the global CEPI partnership is broadening its investment in programs that it hope will result in the rapid development and licensing of new vaccines.